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Abstract
Introduction Hormonal factors are implicated in tumor
progression and it is possible that factors influencing breast
cancer induction could affect prognosis. Our study investigated
the effects of menstrual risk factors on tumor characteristics and
survival in postmenopausal breast cancer.
Methods We used a nationwide, population-based, case-case
design of 2,640 Swedish women who were 50 to 74 years old
and had postmenopausal breast cancer during 1993 to 1995.
Follow-up was conducted until 31 December 2000. We used
polytomous multiple logistic regression to investigate the
relationships between menstrual factors (age at menarche,
cycle length, irregular menstruation, lifetime number of
menstrual cycles, and age at menopause), tumor characteristics
(size, grade, estrogen receptor and progesterone receptor [PR]
status, lymph node involvement, and histology), and Cox
proportional hazards modeling for 5-year survival.
Results Younger ages at menarche were significantly
associated with grade and lymph node involvement. Women
with an age at menarche of 11 years or younger had a more than
twofold excess risk of medium-grade (odds ratio [OR] = 2.05;
95% confidence interval [CI] 1.00 to 4.18) and high-grade (OR
= 2.04; 95% CI 1.01 to 4.16) tumors. Early menarche
significantly increased the risk of lymph node metastases.
Survival was poorest in women with the earliest age at
menarche, with a 72% increased risk of dying within 5 years
after diagnosis (hazard ratio = 1.72; 95% CI 1.02 to 2.89). No
significant associations were observed for other menstrual
factors with tumor characteristics or survival.
Conclusions Age at menarche has a significant impact on
breast cancer prognosis and survival. It remains to be
established whether the associations are attributable to age at
menarche directly or are associated with the early-life
physiological events of breast development and carcinogenesis
also taking place during childhood and puberty, as menarche is
only the culmination of this series of events.
Introduction
Haenszel [1] hypothesized that factors influencing breast can-
cer induction also affect prognosis. Estrogen promotes
growth in breast cancer cell lines [2], and lower estrogen lev-
els have been correlated with improved disease-free survival in
postmenopausal breast cancer [3]. Tumor characteristics are
important in determining survival [4], but they explain only a
fraction of the variation observed in survival [5].
Several studies have generated support for Haenszel's
hypothesis, with the confirmed association between obesity
and poorer breast cancer prognosis [6-9]. To date, there have
been conflicting results on whether menstrual risk factors for
breast cancer influence tumor progression and survival in
patients [9-19]. This may be partially due to variations in age
categorizations for age-dependent risk factors, such as age at
menarche and age at menopause, making interpretation diffi-
cult since there may be a critical time window of susceptibility
during adolescent and puberty development that influences
tumor initiation and progression.
The question of whether menstrual risk factors influence
breast cancer prognosis is timely due to the decreasing age at
menarche [20], with changes in nutrition [21] and lifestyle [22]Page 1 of 9
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tion on tumor characteristics and survival outcomes have been
conducted, nor have there been many large or population-
based studies to address these research questions. There-
fore, our study investigated the effects of menstrual risk factors
on the prognostic significance of breast cancer in a popula-
tion-based cohort of 2,640 patients with complete and
detailed follow-up. This is the first study of its kind to address
menstrual factors across a woman's lifespan, with detailed
information regarding age at menarche, menstrual cycle
length, irregular menstruation, lifetime menstrual cycles, and
age at menopause and to equate to cumulative lifetime expo-
sure to hormones acting on the breast.
Materials and methods
Study design
This study is an extension of a population-based case-control
study among all women who were born in Sweden and who
were 50 to 74 years of age between 1 October 1993 and 31
March 1995 and is described in detail elsewhere [23,24]. We
used a case-case design in which we obtained odds ratios
(ORs) and estimated hazard ratios (HRs), as measures of rel-
ative risk comparing breast cancer cases' categories of men-
strual factors, to investigate the relationships between
menstrual factors, tumor characteristics, and 5-year breast
cancer survival.
Participants
Women with incident primary invasive breast cancer were
identified through the six Swedish Regional Cancer Registries
and contacted by their doctors. Out of 3,979 women with a
primary diagnosis of invasive breast cancer, 3,345 women
(84%) participated in the study. The primary reason for non-
participation was patient's or doctor's refusal due to patient ill
health. Excluded patients had previous or other tumors (151
cases), noninvasive breast cancer according to patient
records from the regional cancer registry (58 cases), a diagno-
sis outside the study period (19 cases), lack of patient consent
(58 cases), premenopausal status (198 cases), being younger
than 55 years with an unknown age at menopause (202
cases), missing age at first birth (5 cases), and missing height
or recent weight (14 cases). The study included 2,640 eligible
postmenopausal breast cancer patients of European descent.
Protocol
The ethical review board at the Karolinska Institute (Stock-
holm, Sweden) and the six ethical review boards in other
regions of Sweden approved the study. Prior to participation
via a mailed questionnaire, written consent was obtained from
all patients. The mean interval between diagnosis and data col-
lection was 4.3 months (standard deviation of 1.5 months).
Data collection and classification
With the exception of clinical data on tumor characteristics
and follow-up data for survival outcomes, exposure and covari-
ate data used in this study were derived from the case-control
study questionnaire. In brief, data on sociodemographic,
anthropometric, reproductive, and menstrual factors, use of
oral contraceptives, and medical history (1 year prior to data
collection) were collected by means of a postal questionnaire.
Detailed information pertaining to the use of menopausal hor-
mone therapy (MHT), including timing and type of hormones
for each treatment episode, was requested along with a color
chart that displayed all preparations ever marketed in Sweden
and that was included with the questionnaire to facilitate recall.
Additionally, approximately 50% of cases were contacted by
telephone to complete missing or ambiguous responses,
mainly on the use of MHT.
Menstrual factors assessed were age at menarche, age at
menopause, irregular menstruation, cycle length, and lifetime
number of menstrual cycles. Age at menarche was classified
as not older than 11 years, older than 11 but not older than 13
years, older than 13 but not older than 14 years, and older than
14 years. Menopause was defined as the age at last menstrual
period or age at bilateral oophorectomy if at least 1 year prior
to data collection. To ensure an accurate classification of the
true age at menopause, analyses for age at menopause were
firstly restricted to women with known natural or surgical age
at menopause who had not used MHT prior to menopause.
Due to the large percentage of women with a missing true age
at menopause (39%), we decided to use all women with an
age at menopause and adjust our analyses for use and type of
MHT. Age at menopause was grouped as younger than 50
years, 50 to 55 years, and older than 55 years. Irregular men-
struation was either absent or present during the lifetime.
Cycle length was classified as not more than 27.5 days per
cycle, 28 days per cycle, or more than 28 days per cycle. Life-
time number of menstrual cycles was a created variable
derived from all women with known values for age at
menarche, age at menopause, parity, and cycle length and did
not include those women with irregular menstruation or mis-
carriages and/or abortions. Lifetime number of menstrual
cycles was classified as not more than 423 cycles per lifetime,
more than 423 but not more than 500 cycles, and more than
500 cycles.
Information regarding tumor characteristics was retrieved from
the medical records of all participants from surgical and onco-
logical units throughout Sweden. Data pertaining to tumor
characteristics included tumor size, grade (classified accord-
ing to the Nottingham histological grade or Bloom-Richardson
scale), estrogen receptor (ER) and progesterone receptor
(PR) status, and lymph node involvement. Information on grade
was not in routine use in Sweden during the study period and
is therefore missing in 33% of patients.
The Swedish National Registration Number, a unique 10-digit
number for each Swedish resident, was used to link the cohort
with the Swedish National Population Register and the Swed-Page 2 of 9
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on the dates and causes of death, respectively. The latter reg-
ister covers all residents in Sweden and has been shown to
accurately classify 98% of all breast cancer deaths [25].
Statistical analyses
Tumor presentation
The significance of differences between tumor characteristics
and menstrual factors was evaluated using frequencies with
chi-square tests of association. All probability values of P less
than 0.05 were considered significant. ORs with 95% confi-
dence intervals (CIs) were calculated using polytomous multi-
ple logistic regression [26], with tumor characteristics as the
dependent variables, with the category of each tumor charac-
teristics having the best prognosis as the reference group, and
with the remaining categories as the outcome. Potential con-
founders were included in the models in a step-wise approach
based on established biological knowledge of confounders
particular to the associations of interest between menstrual
risk factors and prognostic tumor characteristics, rather than
solely based on a 10% percentage shift in the estimates.
Survival analysis
Follow-up time began on the date of breast cancer diagnosis
and ended on the date of death, date of emigration, or date of
study truncation or 5 years after the date of diagnosis, which-
ever occurred earlier. The outcome was breast cancer-specific
deaths (International Classification of Diseases [ICD]-9: 174.9
and ICD-10: C50.9). One woman emigrated, 264 died from
breast cancer, and 383 died from other causes during 12,290
person-years of follow-up.
Breast cancer mortality rates were calculated by menstrual
factors as the number of breast cancer deaths per 100 per-
son-years. Cumulative 5-year survival rates were calculated
using the Kaplan-Meier method, and the significance of differ-
ences in survival was evaluated using the log-rank test. The
Cox proportional hazards regression model was used to quan-
tify the effects of menstrual factors on 5-year survival. The cov-
ariates chosen for multivariate analysis adjustments were
based on biological associations deemed important in assess-
ing menstrual factors and survival.
The menstrual prognostic factors in our study all occurred
prior to the diagnosis of breast cancer. Therefore, any effects
on tumor progression would have been mediated through the
biological characteristics of the tumor itself. Hence, adjusting
for any tumor characteristic variables in the Cox regression
model would be incorrect as they did not confound the asso-
ciation between menstrual factors and breast cancer survival
but rather acted as intermediates in the causal pathway.
STATA® version 9.2 (Statacorp, Texas, USA) was used for
data analyses.
Results
All menstrual factors were analyzed in relation to tumor char-
acteristics and 5-year survival. Cycle length, total lifetime
number of menstrual cycles, irregular menstruation, and age at
menopause showed no significant trends, with most estimates
close to unity. Therefore, only the results of survival analyses
will be presented for these menstrual factors.
Background reproductive and menstrual factors of all cases in
relation to age at menarche are summarized in Table 1. The
majority of cases experienced menarche from more than 11 to
not more than 13 years of age and from more than 13 to not
more than 14 years of age (989 and 698 cases, respectively),
with 9% missing age at menarche. In total, 264 deaths from
breast cancer occurred. Fourteen percent of deaths occurred
in women with the earliest age at menarche, 9% and 10%
occurred in those with an intermediate age at menarche (from
more than 11 to not more than 13 years and from more than
13 to not more than 14 years, respectively), and 8% in those
with the oldest age at menarche.
Age at menarche and tumor characteristics
The associations of age at menarche and tumor characteris-
tics of breast cancer patients are summarized in Table 2. Age
at menarche was significantly associated with grade and
lymph node involvement. ORs of the relation of age at
menarche and tumor characteristics are summarized in Table
3. Only adjusted models are presented in the table as unad-
justed estimates were virtually unchanged. Women with an
age at menarche of not more than 11 years had a greater than
twofold increased risk for tumors of medium grade (OR =
2.05; 95% CI 1.00 to 4.19) and high grade (OR = 2.04; 95%
CI 1.01 to 4.16) compared with women with the oldest age at
menarche with a low tumor grade. Similarly, women with inter-
mediate ages at menarche had significantly increased risks for
medium-grade tumors (OR = 1.47 [95% CI 1.00 to 2.15] in
those older than 11 and not older than 13 years and OR =
1.74 [95% CI 1.15 to 2.62] in those older than 13 and not
older than 14 years) and high-grade tumors (OR = 1.55 [95%
CI 1.06 to 2.26] in those older than 11 and not older than 13
years and OR = 1.45 [95% CI 1.00 to 2.19] in those older
than 13 and not older than 14 years). Women with earlier ages
at menarche were also at a significantly increased risk for hav-
ing tumors with lymph node involvement (OR = 1.49 [95% CI
1.02 to 2.19] and OR = 1.29 [95% CI 1.02 to 1.65] for the
earliest age at menarche and for the age at menarche of more
than 11 and not more than 13 years, respectively) compared
with those oldest at menarche with no nodal involvement.
Menstrual risk factors and survival
Kaplan-Meier survival curves showed significant differences in
survival between the youngest and oldest ages at menarche (P
value for log-rank test = 0.0466). As determined using a Cox
model (Table 4), survival was poorest in women with the earli-
est age at menarche, with a 72% increased risk of dying withinPage 3 of 9
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Table 1
Distribution of background factors in postmenopausal women diagnosed with breast cancer in relation to age at menarche
Age at menarche, years P valuea
 11 > 11 and 13 > 13 and 14 > 14
Column frequency, number (percentage)
Total number of cases (n = 2,640) 167 989 698 542
Background factors
Menstrual cycle length, days
27.5 35 (30) 183 (26) 125 (26) 93 (26)
28 64 (55) 392 (55) 258 (54) 191 (54)
> 28 17 (15) 136 (19) 96 (20) 71 (20) 0.877
Irregular menstruation
No 159 (96) 39 (4) 18 (3) 518 (98)
Yes 7 (4) 940 (96) 672 (97) 13 (2) 0.246
Age at first birth, years
< 25 73 (51) 418 (50) 268 (45) 226 (49)
25 and < 30 44 (31) 281 (34) 200 (34) 149 (32)
30 27 (19) 136 (16) 129 (21) 86 (19) 0.240
Parity
0 23 (14) 154 (16) 101 (14) 81 (15)
1 30 (18) 215 (21) 154 (22) 105 (19)
2 68 (41) 362 (37) 269 (39) 215 (40)
3+ 46 (28) 258 (26) 174 (25) 141 (26) 0.893
Pregnancy terminated < 6 months, nulliparous
No 7 (88) 15 (38) 18 (49) 9 (45)
Yes 1 (12) 25 (62) 19 (51) 11 (55) 0.079
Pregnancy terminated < 6 months, parous
No 100 (71) 631 (76) 431 (73) 363 (79)
Yes 40 (29) 197 (24) 160 (27) 95 (21) 0.069
Age at menopause, yearsb
< 50 45 (31) 261 (31) 198 (34) 133 (28)
50–55 86 (59) 520 (62) 344 (58) 299 (63)
> 55 14 (10) 55 (7) 47 (8) 43 (9) 0.312
Ever use of MHTc
No 105 (63) 646 (66) 483 (69) 370 (68)
Yes 61 (37) 340 (34) 215 (31) 171 (32) 0.258
MHT use by general type
Exclusive estrogen use 14 (9) 67 (7) 54 (8) 39 (8)
Estrogen-progestin combined use 39 (25) 233 (25) 142 (21) 111 (21) 0.566
Diagnosed via mammographic screening
Screening 102 (61) 546 (56) 399 (58) 301 (57)
Other 64 (39) 436 (44) 288 (42) 228 (43) 0.484
Deceased at end of 5-year follow-up 27 (16) 134 (14) 101 (15) 74 (14) 0.802
Breast cancer deaths at end of 5-year follow-up (total = 264) 23 (14) 89 (9) 71 (10) 46 (8) 0.186
aPearson chi-square tests of association between groups. bAmong women with a natural known menopause. cMenopausal hormone therapy 
includes all treatments: exclusive estrogens, exclusive progestins, and combined estrogen-progestin therapy.
Available online http://breast-cancer-research.com/content/10/6/R1075 years of diagnosis (HR = 1.72; 95% CI 1.02 to 2.89). Cycle
length, total lifetime number of menstrual cycles, irregular men-
struation, and age at menopause showed no significant trends
in survival using the Kaplan-Meier method (data not shown) or
Cox modeling (Table 4). Only adjusted estimates for survival
are presented in Table 4 as unadjusted values were virtually
identical.
Discussion
We found age at menarche to be significantly associated with
tumor grade and lymph node involvement. Consistently, an
age at menarche of 11 years or younger had the poorest sur-
vival. No associations were found with cycle length, irregular
menstruation, lifetime number of menstrual cycles, and age at
menopause with tumor characteristics or survival.
This is the first study to investigate menstrual factors of age at
menarche, cycle length, irregular menstruation, lifetime
number of ovulatory cycles, and age at menopause with tumor
characteristics as the outcome. Our findings of significantly
greater risks of higher-grade tumors and the presence of
lymph node involvement with earlier ages at menarche appear
to be novel. Only one study investigated hormone-related
breast cancer risk factors and breast tumor proliferation,
measured by the protein Ki-67 and mitotic count [16]. In con-
trast to our findings, those of that study found no significant
association between tumor proliferation or mitotic count and
age at menarche.
Age at menarche has previously been inconsistently associ-
ated with survival. Similar to our results are those of three other
studies that also found an association between early age at
menarche and reduced survival [10,12,19]. Caleffi and col-
leagues [10] studied women treated with modified radical
mastectomy and found a significantly poorer survival with early
age at menarche. In the study by Juret and colleagues [12], a
Table 2
Association of age at menarche with tumor-defined characteristics of breast cancer
Age at menarche, years
Tumor characteristic 11 > 11 and 13 > 13 and 14 > 14 P valuea
Tumor size
1–10 mm 47 (28) 258 (26) 183 (27) 153 (29)
11–20 mm 76 (46) 414 (43) 302 (44) 250 (47)
21 mm 43 (26) 304 (31) 199 (29) 129 (24) 0.188
Grade
Low 12 (10) 98 (15) 66 (14) 71 (20)
Medium 50 (44) 270 (40) 214 (46) 136 (39)
High 52 (46) 304 (45) 188 (40) 141 (40) 0.037
ER status
Positive 91 (73) 145 (20) 113 (23) 302 (79)
Negative 34 (27) 564 (80) 381 (77) 78 (21) 0.309
PR status
Positive 84 (69) 224 (32) 181 (37) 252 (68)
Negative 38 (31) 473 (68) 305 (63) 121 (32) 0.250
Lymph node involvement
Absent 104 (63) 630 (66) 456 (68) 374 (72)
Present 60 (37) 329 (34) 217 (32) 146 (28) 0.052
Histology
Ductal 124 (75) 692 (71) 503 (73) 383 (72)
Lobular 24 (14) 118 (12) 78 (11) 62 (12)
All other 18 (11) 165 (17) 108 (16) 87 (16) 0.509
aPearson chi-square tests of association between groups. ER, estrogen receptor; PR, progesterone receptor.Page 5 of 9
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reflect a correlation with axillary nodal involvement, a hypothe-
sis that our findings did not reject. The most recent study, by
Trivers and colleagues [19], reported findings parallel to ours
but their study was restricted to women less than 55 years of
age and the association was evident only in premenopausal
women when stratified by menopausal status.
Most other studies found no association with age at menarche
and survival [9,11,15,17,18,27-30] or found an association
opposite to our findings, with older age at menarche being
associated with worse survival [13]. Possible explanations for
the discrepancies in findings could be a difference in distribu-
tion of age at diagnosis, lack of adjustment for potential con-
founders, adjustment for tumor characteristics that are
intermediates in the causal pathway of the association being
addressed, and different categorizations of age at menarche.
It is well established that an early age at menarche is a risk fac-
tor for breast cancer [31]. The effects of age at menarche are
linked to greater exposure to estrogens, which are promoters
of breast cancer [32], as women with an early age at
menarche have long-term increases in serum estradiol and
lower serum sex hormone binding globulin (SHBG) concen-
trations than women with a late age at menarche [33]. These
hormone levels prevail throughout the second and third dec-
ades of life [33]. We hypothesize that possible similar mecha-
nisms act on breast carcinogenesis at earlier ages of
menarche to influence the development and programming of
tumors.
Table 3
Relation of age at menarche to tumor-defined characteristics of breast cancer
Age at menarche, years
Odds ratio (95% confidence interval)a, b
Tumor characteristic 11 > 11 and 13 > 13 and 14
Tumor size
1–10 mm
11–20 mm 1.00 (0.65–1.53) 0.96 (0.74–1.25) 1.01 (0.76–1.33)
21 mm 1.05 (0.64–1.72) 1.43 (1.06–1.92) 1.32 (0.96–1.81)
Grade
Low
Medium 2.05 (1.00–4.19) 1.47 (1.00–2.15) 1.74 (1.15–2.62)
High 2.04 (1.01–4.16) 1.55 (1.06–2.26) 1.45 (1.00–2.19)
ER status
Positive
Negative 1.33 (0.82–2.16) 0.94 (0.68–1.29) 1.15 (0.83–1.61)
PR status
Positive
Negative 0.86 (0.54–1.36) 0.99 (0.75–1.30) 1.24 (0.93–1.66)
Lymph node involvement
Absent
Present 1.49 (1.02–2.19) 1.29 (1.02–1.65) 1.22 (0.95–1.58)
Histology
Ductal
Lobular 1.17 (0.68–2.01) 1.08 (0.76–1.52) 0.99 (0.68–1.43)
All other 0.68 (0.39–1.18) 1.09 (0.81–1.46) 0.92 (0.66–1.26)
aReference group: age at menarche of more than 14 years, with the category of best prognosis within each tumor characteristic. bOdds ratio 
estimates adjusted for body mass index at 18 years of age, age at first birth, age at diagnosis, and ever use and type of menopausal hormone 
therapy (never users, exclusive estrogen therapy, and combined estrogen-progestin therapy). ER, estrogen receptor; PR, progesterone receptor.Page 6 of 9
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of a series of hormonal, somatic, and anthropometric changes
[34] and that early puberty, breast development, and
menarche follow a naturally occurring process predetermined
by a biological clock that, once initiated, turns on a rather inde-
pendent process of breast development and maturation [35].
Puberty is a critical period in breast carcinogenesis [36] pos-
sibly explained by a very high number of terminal duct lobular
units (that is, the functional units of the breast with the greatest
proliferative activity [37] and the origin of most tumors [38]).
Berkey and colleagues [39] hypothesized that rapid physical
growth during adolescence gives less time for repair of DNA
and thereby does permanent DNA damage with a carcino-
genic potential. A recent study by Ahlgren and colleagues [40]
showed that, after accounting for the growth patterns during
childhood and adolescence, age at menarche was not related
to risk of breast cancer. Similarly, we hypothesize that we can-
not rule out the effects of puberty and growth during childhood
and adolescence on the impressionable breast and that it is
during this critical time window of susceptibility not only that
breast carcinogenesis is initiated, but that tumor biology and
prognosis are determined.
Furthermore, our findings that the total number of lifetime men-
strual cycles a woman experiences is not associated with
tumor characteristics and survival lend further support to the
hypothesis of a critical time window of susceptibility acting on
breast carcinogenesis and prognosis as opposed to the
'estrogen augmented by progesterone' hypothesis [41] of
cumulative lifetime exposure to estrogens and progesterone
through regular ovulatory cycles, since all estimates were
close to unity.
Our results for age at menarche were adjusted for body mass
index (BMI) at 18 years of age as BMI could be a confounder
in the association of age at menarche and tumor characteris-
tics and survival. Strictly speaking, BMI at 18 years is chrono-
logically after menarche. However, in our study, we used this
BMI as a proxy for childhood obesity. Thus, our results assume
that no drastic changes in BMI occurred between childhood
Table 4
Breast cancer-specific five-year survival in relation to menstrual factors
Menstrual factors Deaths Mortality ratea Hazard ratio (95% CI)b
Age at menarch, yearsc
> 14 46 1.81 1.00 (reference)
> 13 and 14 71 2.19 1.26 (0.86–1.84)
> 11 and 13 89 1.93 1.14 (0.79–1.65)
11 23 2.99 1.72 (1.02–2.89)
Irregular menstruation
No 253 2.16 1.00 (reference)
Yes 7 1.77 0.91 (0.43–1.93)
Cycle length, days
27.5 39 1.79 1.00 (reference)
28 95 2.16 1.15 (0.78–1.68)
> 28 29 1.78 0.98 (0.60–1.61)
Total lifetime menstrual cycles, number
423 58 2.10 1.00 (reference)
> 423 and 500 104 2.00 0.99 (0.71–1.38)
> 500 57 2.09 1.04 (0.72–1.52)
Age at menopause, years
< 50 79 2.43 1.00 (reference)
50–55 138 2.18 0.92 (0.69–1.22)
> 55 17 2.22 1.04 (0.60–1.80)
aBreast cancer deaths per 100 person-years. bAll menstrual factor hazard ratio estimates adjusted for age at first birth, age at diagnosis, ever use 
and type of menopausal hormone therapy (never users, exclusive estrogen therapy, and combined estrogen-progestin therapy).cAge at menarche 
hazard ratio estimates additionally adjusted for body mass index at 18 years of age.Page 7 of 9
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affected by BMI as ovulation and menstruation require a
threshold weight [22]. An increased body fat mass has been
associated with early puberty and menarche [22,42]. Findings
from a recent study substantiate the notion that body adipos-
ity, possibly partly through hyperleptinemia, and insulin resist-
ance are key contributors to observed variations in the timing
of menarche [42]. Likewise, adiposity during childhood, at age
18, and premenopausally is associated with a decreased risk
of premenopausal breast cancer, but the association with
postmenopausal breast cancer remains inconclusive [40,43].
Ahlgren and colleagues [40] reported a significant reduction
in risk of postmenopausal breast cancer with a larger BMI at
age 14. Similarly, in another study, increased body silhouettes
at ages 8 and around menarche were associated with a
decreased risk of postmenopausal breast cancer [44]. How-
ever, Velie and colleagues [34] reported that few studies
examined the effects of childhood growth in postmenopausal
women exclusively, and that many studies do not yet contain
older postmenopausal women. Additionally, these authors
acknowledge the difficulties in extricating the effects of child-
hood body size from correlated adult body size with breast
cancer risk. Similarly, as for risk, BMI is associated with prog-
nosis [6-8]. Recent evidence suggests that excess body fat
promotes the growth of breast tumors, with worse survival out-
comes [6-8]. In our study, we cannot exclude the possibility
that age at menarche could be an intermediary in the associa-
tion between childhood BMI and prognosis. However, control-
ling for BMI at diagnosis did not attenuate the observed
effects of age at menarche on tumor characteristics and sur-
vival. Our finding that age at menopause is not associated with
survival is consistent with results from all previous studies
[9,11,15,17,28,29], except one [13], which found that early or
late age at menopause was associated with a poorer survival
compared with women with menopause between the ages of
46 and 54 years.
Strengths and limitations
Our study was population-based with a high response rate
among cases (84%). Detailed information was available on
menstrual risk factors in addition to other breast cancer risk
factors. Sound information on tumor characteristics was col-
lected, with only 2% and 3% of participants missing data on
tumor size and lymph node involvement, respectively.
However, one limitation of our study was that nonparticipants
had somewhat larger tumors on average and therefore these
tumors were more likely to be receptor-negative with a higher
proportion of lymph node involvement. We lacked information
on tumor grade in 33% of cases. However, as all menstrual
exposures assessed occurred well before the diagnosis of
breast cancer, this would have had a negligible effect on our
estimates. Similarly, receptor status was missing for 30% of
cases, with estimates similar to those risks for developing ER-
negative and PR-negative tumors. Receptor status was
assessed at seven different laboratories, and several patholo-
gists classified tumor size, lymph node involvement, and grade
of differentiation. However, misclassification due to the non-
standardized analyses, together with the distribution of miss-
ing information, was certainly unlikely to be related to
menstrual risk factors and is therefore nondifferential. For our
analyses into lifetime number of menstrual cycles, we were not
able to assess the effects of exclusivity of breastfeeding on
breast cancer prognosis. In our study, we cannot exclude the
possibility that our results are due to chance. However, we feel
that this is unlikely since our findings were significant only for
one menstrual factor (age at menarche) as we clearly showed
significant findings, using two different methodologies and
outcomes (which were biologically related), of poorer tumors
and survival, and this is consistent with the interpretation of a
poorer prognosis. All other menstrual factors addressed
showed no significant finding for tumor characteristics or sur-
vival, with most estimated being around unity. Finally, we did
not have childhood, pubertal, and adolescent somatic and
anthropometric data to be able to disentangle whether the
worse tumor characteristics observed in our study were due to
these somatic and anthropometric factors themselves, or
whether age at menarche, serves only as a proxy for these
somatic and anthropometric factors: of which, these may be
even more critical to breast cancer etiology.
Conclusion
We found age at menarche to be significantly associated with
grade and lymph node involvement and we found survival to be
poorest in women with the earliest age at menarche. The find-
ing of our study is timely due to the decreasing age at
menarche in most developed countries and emphasizes the
importance of potential early-life influences on breast tumor
characteristics and survival.
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